Difference between revisions of "Belinostat (Beleodaq)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "==Mechanism of action== Histone deacetylase inhibitor ==Also known as== PXD101 ==History of changes in FDA indication== *7/3/2014: Granted accelerated approval for the treat...")
 
m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information")
 
(29 intermediate revisions by 5 users not shown)
Line 1: Line 1:
==Mechanism of action==
+
==General information==
Histone deacetylase inhibitor
+
Class/mechanism: Histone deacetylase (HDAC) inhibitor. Belinostat causes cell cycle arrest and/or apoptosis of tumor cells by blocking HDAC, which results in accumulation of acetylated histones and other proteins.<ref name=insert>[https://beleodaq.com/wp-content/uploads/2019/11/PI-BELEODAQ-200120.pdf Belinostat (Beleodaq) package insert]</ref><ref>[[:File:Belinostat.pdf | Belinostat (Beleodaq) package insert (locally hosted backup)]]</ref><ref>[http://beleodaq.com/ Beleodaq manufacturer's website]</ref>
 +
<br>Route: IV
 +
<br>Extravasation: no information
  
==Also known as==
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref>
PXD101
+
 
 +
==Diseases for which it is established ''(work in progress)''==
 +
*[[Peripheral T-cell lymphoma]]
 +
 
 +
==Diseases for which it is used==
 +
*[[Cutaneous T-cell lymphoma]]
 +
 
 +
==Patient drug information==
 +
*[https://beleodaq.com/wp-content/uploads/2019/11/PI-BELEODAQ-200120.pdf Belinostat (Beleodaq) package insert]<ref name=insert></ref>
 +
*[https://chemocare.com/druginfo/belinostat.aspx Belinostat (Beleodaq) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/belinostat.aspx Belinostat (Beleodaq) patient drug information (Chemocare)]</ref>
 +
*[http://www.uptodate.com/contents/belinostat-patient-drug-information Belinostat (Beleodaq) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/belinostat-patient-drug-information Belinostat (Beleodaq) patient drug information (UpToDate)]</ref>
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
*7/3/2014: Granted accelerated approval for the treatment of patients with relapsed or refractory [[T-cell lymphoma | peripheral T-cell lymphoma  
+
*2014-07-03: [http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm403929.htm FDA accelerated approval] for the treatment of patients with relapsed or refractory [[Peripheral_T-cell_lymphoma | peripheral T-cell lymphoma (PTCL)]]. ''(Based on BELIEF)''
(PTCL)]].
+
 
 +
==Also known as==
 +
*'''Code name:''' PXD-101
 +
*'''Brand name:''' Beleodaq
  
[[Category:HDAC inhibitors]]
+
==References==
 +
<references/>
  
[[Category:T-cell lymphoma medications]]
+
[[Category:Drugs]]
  
[[Category:Drugs FDA approved in 2014]]
+
[[Category:Intravenous medications]]
 +
[[Category:HDAC inhibitors]]
 +
[[Category:Cutaneous T-cell lymphoma medications]]
 +
[[Category:Peripheral T-cell lymphoma medications]]
 +
[[Category:FDA approved in 2014]]

Latest revision as of 00:58, 29 June 2024

General information

Class/mechanism: Histone deacetylase (HDAC) inhibitor. Belinostat causes cell cycle arrest and/or apoptosis of tumor cells by blocking HDAC, which results in accumulation of acetylated histones and other proteins.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code name: PXD-101
  • Brand name: Beleodaq

References